About Cytiva
PURIDIFY WAS ACQUIRED BY GE HEALTHCARE, NOW CYTIVA IN 2017
Global demand for cheaper biotherapeutics drives the need for bioprocessing cost reduction, a significant proportion of which comes from chromatography reagents and their operation.
• Puridify uses nanofibre technology to create purification solutions for biotherapeutic manufacturing.
• Puridify's chromatography reagent, FibroSelect, reduces bioprocessing costs for manufacturers.
• FibroSelect offers substantial productivity increase in purification whilst making minimal changes to current best practice.
Advertisement
